The Food and Drug Administration (FDA) has approved a 600 mg tablet version of the protease inhibitor Prezista (darunavir), sold by Tibotec, thus reducing the number of pills a person must take each day. Currently, people taking Prezista must take two 300 mg tablets along with 100 mg of Norvir (ritonavir) twice a day. The company will continue to make the 300 mg tablet version. The new 600 mg tablet is expected to hit pharmacy shelves sometime in May.